BRPI0611717A2 - composto, composiÇço farmacÊutica e uso do composto - Google Patents

composto, composiÇço farmacÊutica e uso do composto

Info

Publication number
BRPI0611717A2
BRPI0611717A2 BRPI0611717-1A BRPI0611717A BRPI0611717A2 BR PI0611717 A2 BRPI0611717 A2 BR PI0611717A2 BR PI0611717 A BRPI0611717 A BR PI0611717A BR PI0611717 A2 BRPI0611717 A2 BR PI0611717A2
Authority
BR
Brazil
Prior art keywords
compound
compounds
pharmaceutical composition
akt
inhibit
Prior art date
Application number
BRPI0611717-1A
Other languages
English (en)
Inventor
Donna J Armstrong
Essa H Hu
Michael J Kelly
Mark E Layton
Yiwei Li
Jun Liang
Kevin J Rodzinak
Michael A Rossi
Philip E Sanderson
Jiabing Wang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0611717A2 publication Critical patent/BRPI0611717A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTO, COMPOSIÇçO FARMACÊUTICA E USO DO COMPOSTO. A presente invenção provê compostos nafliridina substituidos que inibem a atividade de Akt. Em particular, os compostos descritos seletivamente inibem uma ou duas das isoformas de Akt. A invenção também provê composições compreendendo estes compostos inibidores e métodos de inibir a atividade de Akt por administração dos compostos a um paciente em necessidade de tratamento de câncer.
BRPI0611717-1A 2005-06-10 2006-06-07 composto, composiÇço farmacÊutica e uso do composto BRPI0611717A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07
PCT/US2006/022079 WO2006135627A2 (en) 2005-06-10 2006-06-07 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
BRPI0611717A2 true BRPI0611717A2 (pt) 2009-01-13

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611717-1A BRPI0611717A2 (pt) 2005-06-10 2006-06-07 composto, composiÇço farmacÊutica e uso do composto

Country Status (22)

Country Link
US (1) US8008317B2 (pt)
EP (1) EP1898903B8 (pt)
JP (1) JP5055494B2 (pt)
KR (1) KR100959771B1 (pt)
AU (1) AU2006258124B8 (pt)
BR (1) BRPI0611717A2 (pt)
CA (1) CA2610888C (pt)
CR (1) CR9580A (pt)
DK (1) DK1898903T3 (pt)
EC (1) ECSP077980A (pt)
ES (1) ES2409168T3 (pt)
HR (1) HRP20130429T1 (pt)
IL (1) IL187690A (pt)
MX (1) MX2007015578A (pt)
NI (1) NI200700320A (pt)
NO (1) NO20080150L (pt)
NZ (1) NZ563423A (pt)
PL (1) PL1898903T3 (pt)
PT (1) PT1898903E (pt)
RU (1) RU2421454C2 (pt)
TW (1) TW200800166A (pt)
WO (1) WO2006135627A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
CA2670767A1 (en) * 2006-12-06 2008-06-12 Merck & Co., Inc. Inhibitors of akt activity
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UY31293A1 (es) 2007-08-14 2009-03-31 Pirimidinas biciclicas fusionadas
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2726358A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2009255358A1 (en) * 2008-06-03 2009-12-10 Msd K.K. Inhibitors of Akt activity
BRPI0916218B1 (pt) 2008-07-17 2018-11-27 Bayer Cropscience Ag compostos heterocíclicos como composições praguicidas
WO2010088177A1 (en) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR20110114663A (ko) 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
EP2396331B1 (en) 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Fused pyrimidines as akt inhibitors
EP2403339B1 (en) * 2009-03-06 2017-01-18 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
WO2010104933A1 (en) * 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2405756B1 (en) 2009-03-12 2013-07-03 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
EP2473495A1 (en) 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
EP2513059A4 (en) * 2009-12-17 2013-06-05 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
JP5830094B2 (ja) * 2010-07-12 2015-12-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ａ］ピリミジンおよび−ピリジン
BR112013000925A2 (pt) * 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
EA024890B1 (ru) 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
KR102123131B1 (ko) * 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
RU2644769C2 (ru) 2013-01-23 2018-02-14 Астразенека Аб Химические соединения
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3091016A1 (en) * 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
MX2024005207A (es) * 2021-11-05 2024-07-24 Georgiamune Inc Moduladores de akt3.
WO2025196161A2 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2025196160A1 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
DE69525978T2 (de) * 1995-06-06 2002-12-19 Pfizer Trizyclische 5,6-dihydro-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-alpha)pyridine
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
ATE400274T1 (de) 2001-04-10 2008-07-15 Merck & Co Inc Hemmstoffe der akt aktivität
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003086394A1 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
JP4679514B2 (ja) * 2003-04-24 2011-04-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
WO2004096131A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
CN1809351A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
DE602004026047D1 (de) 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
CN1942470A (zh) 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
AU2005290081B2 (en) * 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2008521917A (ja) 2004-12-02 2008-06-26 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性のインヒビター
WO2006065601A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
AU2006216998B2 (en) * 2005-02-14 2010-12-23 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2602197A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibitors of akt activity
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
JP2009501698A (ja) 2009-01-22
AU2006258124A1 (en) 2006-12-21
EP1898903A2 (en) 2008-03-19
KR20080016627A (ko) 2008-02-21
CR9580A (es) 2008-09-23
CA2610888A1 (en) 2006-12-21
PT1898903E (pt) 2013-06-28
WO2006135627A3 (en) 2008-07-31
EP1898903B1 (en) 2013-03-27
JP5055494B2 (ja) 2012-10-24
RU2421454C2 (ru) 2011-06-20
IL187690A0 (en) 2008-11-03
AU2006258124B8 (en) 2010-01-07
HRP20130429T1 (en) 2013-06-30
US20100222321A1 (en) 2010-09-02
NZ563423A (en) 2010-05-28
US8008317B2 (en) 2011-08-30
EP1898903A4 (en) 2010-07-21
WO2006135627A2 (en) 2006-12-21
CA2610888C (en) 2011-02-08
NO20080150L (no) 2008-03-10
ES2409168T3 (es) 2013-06-25
NI200700320A (es) 2008-06-17
AU2006258124B2 (en) 2009-09-03
MX2007015578A (es) 2008-03-06
RU2008100045A (ru) 2009-07-20
DK1898903T3 (da) 2013-07-01
EP1898903B8 (en) 2013-05-15
TW200800166A (en) 2008-01-01
IL187690A (en) 2012-06-28
ECSP077980A (es) 2008-01-23
KR100959771B1 (ko) 2010-05-28
PL1898903T3 (pl) 2013-08-30

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
SV2011003786A (es) Compuestos quimicos 251
CR9580A (es) Inhibidores de la actividad akt
WO2006091395A3 (en) Inhibitors of akt activity
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
BRPI0519424B8 (pt) compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112012006010A2 (pt) composto de glicina
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
WO2006110638A3 (en) Inhibitors of akt activity
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]